drugset / Trial / NCT01001208

The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis

NCT01001208

Phase 3 Completed 478 enrolled Amgen Immunex Corporation · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of adding methotrexate to etanercept compared with etanercept monotherapy as measured by the percentage of participants achieving a 75% improvement from baseline in the Psoriasis Area and Severity Index (PASI 75) at Week 24.

Timeline

Start
2009-11
Primary completion
2010-12
Completion
2011-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous
Subject Methotrexate Small molecule 15 mg

Indications